ADHD and peptides on TikTok: separating signal from noise

What did @calxshreds actually say?

@calxshreds, who says they have diagnosed ADHD, listed four compounds they personally use: retatrutide at "two milligrams per week," selank and semax together for cognitive function, "mydafodil" (modafinil) at 250mg daily, and methylene blue for mitochondrial support and cognition. They framed all of this as personal experience, not medical advice, and told viewers to "do your own research."

To their credit, they repeated the personal-experience disclaimer twice and did not tell anyone to copy their exact stack. That said, walking through specific doses of unregulated peptides and a controlled substance on TikTok to 3.6K viewers does real-world work regardless of how many disclaimers are attached. Intent and impact are different things.

Does the science back this up?

Partially, for some compounds. Not at all for others. The evidence base here ranges from genuinely interesting early-stage research to near-zero human data.

Retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors) currently in Phase 2 trials for obesity. The claim that it helps with ADHD and impulse control is based on extrapolation from GLP-1 receptor agonist research. There is some signal: a 2023 observational study by Giel et al. in Nature Mental Health found GLP-1 agonist users had lower rates of substance use disorder, which could loosely relate to impulse control. But retatrutide specifically has no published human ADHD data.

Selank is a synthetic heptapeptide developed in Russia with anxiolytic properties studied primarily in Russian-language literature and animal models. Dolotov et al. (2006, Journal of Neurochemistry) showed modulation of enkephalin levels in rats. Human RCT data is thin. Semax has a similar profile: real neurochemical activity in rodents, limited rigorous human trials outside Eastern European research settings.

Methylene blue does have legitimate mitochondrial and cognitive research behind it. Gonzalez-Lima and Barksdale (2011, European Journal of Pharmacology) demonstrated memory enhancement in rodents. Tucker et al. (2018, Frontiers in Aging Neuroscience) showed some benefit in early Alzheimer's models. Applying that to ADHD management is a stretch.

What did they get wrong (or right)?

They got the modafinil framing wrong, or at least incomplete. Modafinil is a Schedule IV controlled substance in the US. It is prescribed off-label for ADHD in some cases, but it is not approved for ADHD, and 250mg daily without mentioning it requires a prescription is a meaningful omission for a public-facing video.

The retatrutide claim is the shakiest. Saying it "massively, massively helped my impulse control" based on addiction studies that do not involve retatrutide, and presenting it casually alongside a dose, overstates what the literature actually supports. GLP-1 receptor agonist research on addiction and impulse control is legitimately interesting, but retatrutide is not the same as semaglutide or liraglutide, and no one should be inferring a dose from a TikTok video.

Where they were reasonable: selank and semax do have neurochemical mechanisms that are plausible for cognitive effects. The framing of "raises dopamine and serotonin levels" is oversimplified but not entirely fabricated. And the methylene blue cognition angle, while overstated for ADHD specifically, is grounded in real (if preliminary) science.

What should you actually know?

None of these compounds are FDA-approved treatments for ADHD. Peptides like selank and semax exist in a regulatory gray zone in the US and are not approved for any indication. Retatrutide is an investigational compound, not commercially available outside clinical trials. Using it outside a trial context raises serious questions about sourcing and quality control that the video does not address.

Modafinil being in this stack matters. It is a controlled substance, and combining it with multiple peptides that influence neurotransmitter systems is not something with any documented safety profile. The interaction risk is unknown, not zero.

If you have ADHD and want non-stimulant options, there are actually FDA-approved ones: atomoxetine, viloxazine, guanfacine, clonidine. There is also a growing (cautious) literature on omega-3 supplementation. None of those appeared in this video.

"Do your own research" is not a safety net. When someone describes a specific dose of an investigational compound to an audience, the burden of accuracy does not transfer to the viewer just because a disclaimer was added.